Keynote Lecture 

Future technologies to deepen gut microbiome research 

With the progress of genome science, the study of gut microorganisms has shifted from isolation and identification to a bird's eye view of the microbiota and microbiome. In the future, the knowledge of intestinal microbiota and diseases and health will be further deepened through genomic analysis at the single-cell level, metabolomics analysis of a vast number of molecules, and information science such as cohort studies to reveal the relationship between health conditions and diseases and intestinal microbiota. In this seminar, we would like to introduce examples of these research together with research that develop functional molecules and functional microorganisms as concrete tools with an example of probiotics, HYA, development and discuss future trends in gut microbial research.

Research and Development Strategy and Open Innovation at Bayer 

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Pharmaceuticals Division at Bayer is globally conducting research and development activities with the goal of delivering innovative prescription drugs to patients, focusing on the fields of cardiovascular and nephrology, oncology, ophthalmology, gynecology, hematology, and diagnostic imaging.

In addition, Bayer has been promoting open innovation in Japan as one of its key innovation sources since establishing the Open Innovation Center in Japan in 2014. Currently, Bayer has established partnerships with several universities and startup companies and is actively engaged in the creation of innovations through "co-creation" in the field of new modalities and digital technologies. At the same time, Bayer is also working on fostering an innovation ecosystem centered around CoLaborator Kobe, a startup incubator Bayer opened in Kobe in 2018, in close collaboration with a broad spectrum of external stakeholders.

In this seminar, Dr. Christian Rommel, Head of Research and Development of Pharmaceuticals at Bayer AG, will introduce the global R&D strategy in drug development, followed by a presentation on open innovation initiatives in Japan by Shunichi Takahashi, Head of Open Innovation Center Japan at Bayer Yakuhin.

Challenges revealed by COVID-19 - Tackling the next pandemic - 

COVID-19 changed our daily lives and at the same time revealed various problems. Instead of leaving these as issues, we have to prepare for the next by recognizing them again. In this session, each expert will be on stage to talk about the issues and countermeasures for infectious diseases that have become apparent due to COVID-19.

Coordinator

Dr. Ohmagari Norio

Director, Disease Control and Prevention Center
Disease Control and Prevention Center
National Center for Global Health and Medicine

Dx Implementation in the Pharmaceutical Industry 

Coordinator

Astellas Pharma Inc.

Current status of manufacturing and expectations for supporting industries in regenerative medicine  

Coordinator

Dr. Tohru Hirose

Forum for innovative regenerative medicine

iPS Cell Reserch and Development Update 

Regarding iPS cell research, which is being put to practical use, we will talk with the inventor, Professor Yamanaka, and President Takahashi of Vision Care, who is leading the practical use in the field of ophthalmology, and hold a panel discussion on issues and future prospects. This is a session to share with you the cutting edge of industrialization and research of iPS cells.

Coordinator

Prof. Miyata Mitsuru

CEO
Miyata Institute of Technologies,KK

Exploratory healthcare researches by AIST 

Social needs related to healthcare are increasingly diversifying. To help support the medical system and improve QoL, AIST is developing new technologies that contribute to the diagnosis and treatment of diseases and the extension of healthy life expectancy on all scales from molecules to cells and to individuals. In this online seminar, we will introduce highly original studies conducted by 6 young and up-and-coming researchers in the Department of Life Science and Biotechnology.

Creation and commercialization of measurements x AI platform for the science of health 

In the wake of the global spread of the new coronavirus disease, new sensing technologies based on digital technology have been attracting attention. With the advancement of technology, sensors and testing equipment have become smaller, lighter, and more versatile, making it easier for anyone to acquire a variety of data.
In this session, we will focus on products and services that are strategic in terms of "cultivating and expanding ultra-small-signal measurement technology" and "utilizing the acquired data," which are the keys to the future development of the healthcare industry.

Coordinator

Prof. Tsuyoshi Sekitani

Professor
The Institute of Scientific and Industrial Research
Osaka University

The contribution and potential of biotechnology for the realization of a sustainable society 

NEDO believes that it is important to promote, in an integrated and organic manner, three social systems to realize a sustainable society. The three systems are a "circular economy", a "bioeconomy", and "sustainable energy". In this issue, we will introduce the research and development projects that are responsible for each social system from the perspective of biotechnology. We will also consider the contribution and potential of biotechnology in solving climate change issues and realizing a society that continues to develop in a sustainable manner.

Coordinator

Mr. Wataru Mizunashi

Technology Strategy Center
New Energy and Industrial Technology Development Organization

Value creation to the fields of healthcare and manufacturing
- Accelerating data collaboration and data utilization in the field of biotechnology - 

The biotechnology industry is transforming into a data-driven industry with the digital revolution that produces large amounts of data and advances in analytical technology.
In this seminar, two experts will introduce future prospects for the realization of the world's most advanced bio-economy society, while introducing the infrastructure for data utilization in Japan's biotechnology field and examples applied to innovative manufacturing. In addition, we will introduce the construction of the "Data and Biological Resource Platform (DBRP)", a platform that integrates biological resource data for the development of data-driven industries.

Data governance: its importance in digital healthcare 

In a super-aging society it has become an important issue to improve QOL of the elderly, and to optimize social security costs. Companies utilizing big data for digital health care are required to master DATA GOVERNANCE.

Coordinator

Prof. Makoto Suematsu

Professor
School of Medicine
Keio University

Business Strategy of Digital Therapeutics (DTx) 

Coordinator

Dr. Toru Kimura

Representative Director, Executive Vice President, CSO
Sumitomo Dainippon Pharma Co., Ltd.

GCT Outsourcing Success Factors 

Gene and cell therapy (GCT) has the potential to transform medicine by providing long-term, curative treatments for a variety of diseases. GenScript ProBio is developing a GMP platform for the delivery of viral and non-viral vectors. In this seminar, we will introduce how exactly we can make outsourcing a success.

Toward the realization of carbon neutral in 2050 

With the return of the United States to the Paris Agreement, the movement toward decarbonization of the world has accelerated at a stretch, and each country has launched a new strategy, seeing it as an opportunity to grow and gain international competitiveness. Japan has also declared that "Greenhouse gas emissions will be virtually zero by 2050" and the sense of crisis and momentum in the industrial world has increased. In this seminar, we will introduce the Japanese strategy of policy, management, Research and Development, as well as understanding the international situation of decarbonization.

Coordinator

Prof. Kuniki Kino

Professor
Faculty of Science and Engineering
Waseda University